Metal ions, Alzheimer's disease and chelation therapy
By:
Open Access
|Mar 2011References
- D. M. Skovronsky, V. M.-Y. Lee and J. Q. Trojanowski, Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications,
Annu. Rev. Pathol. Mech. Dis. 1 (2006) 151-170; DOI: 10.1146/annurev.pathol.1.110304.100113. - R. Mayeux, Epidemiology of neurodegeneration,
Annu. Rev. Neurosci. 26 (2003) 81-104; DOI: 10.1146/annurev.neuro.26.043002.094919. - C. P. Ferri, R. Sousa, E. Albanese, W. S. Ribeiro and M. Honyashiki,
World Alzheimer Report 2009 - Executive Summary (Eds. M. Prince and J. Jadeson), Alzheimer's Disease International, London 2009, pp. 1-22;http://www.alz.co.uk/adi/publications.html - F. M. LaFerla and S. Oddo, Alzheimer's disease: Aβ, tau and synaptic dysfunction,
Trends Mol. Med. 11 (2005) 170-176; DOI: 10.1016/j.molmed.2005.02.009. - M. Tolnay and A. Probst, Tau protein pathology in Alzheimer's disease and related disorders,
Neuropathol. Appl. Neurobiol. 25 (1999) 171-187; DOI: 10.1046/j.1365-2990.1999.00182.x. - C. Ballatore, V. M.-Y. Lee and J. Q. Trojanowski, Tau-mediated neurodegeneration in Alzheimer's disease and related disorders,
Nature Rev. Neurosci. 8 (2007) 663-672; DOI: 10.1038/nrn2194. - C. W. Scott, A. Fieles, L. A. Sygowski and C. B. Caputo, Aggregation of tau protein by aluminum,
Brain Res. 628 (1993) 77-84; DOI: 10.1016/0006-8993(93)90940-O. - A. Yamamoto, R.-W. Shin, K. Hasegawa, H. Naiki, H. Sato, F. Yoshimasu and T. Kitamoto, Iron (III) induces aggregation of hyperphosphorylated tau, and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease,
J. Neurochem. 86 (2003) 1137-1147; DOI: 10.1046/j.1471-4159.2002.01061.x. - R.-W. Shin, T. P. A. Kruck, H. Murayama and T. Kitamoto, A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease,
Brain Res. 961 (2003) 139-146; DOI: 10.1016/S0006-8993(02)03893-3. - T. Lührs, C. Ritter, M. Adrian, D. Riek-Loher, B. Bohrmann, H. Döbeli, D. Schubert and R. Riek, 3D structure of Alzheimer's amyloid-β (1-42) fibrils,
Proc. Natl Acad. Sci. USA 102 (2005) 17342-17347; DOI: 10.1073/pnas.0506723102. - W. P. Esler and M. S. Wolfe, A portrait of Alzheimer secretases - new features and familiar faces,
Science 293 (2001) 1449-1454; DOI: 10.1126/science.1064638. - M. P. Mattson, Pathways towards and away from Alzheimer's disease,
Nature 430 (2004) 631-639; DOI: 10.1038/nature02621. - M. Shoji, T. Golde, J. Ghiso, T. Cheung, S. Estus, L. Shaffer, X. Cai, D. McKay, R. Tintner and B. Frangione, Production of the Alzheimer amyloid beta protein by normal proteolytic processing,
Science 258 (1992) 126-129; DOI: 10.1126/science.1439760. - C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald and K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome,
Proc. Natl Acad. Sci. USA 82 (1985) 4245-4249; DOI: 10.1073/pnas.82.12.4245. - B. Clippingdale, J. D. Wade and C. J. Barrow, The amyloid-β peptide and its role in Alzheimer's disease,
J. Peptide Sci. 7 (2001) 227-249; DOI: 10.1002/psc.324.abs. - C. Vigo-Pelfrey, D. Lee, P. Keim, I. Lieberburg and D. B. Schenk, Amyloid peptide from human cerebrospinal fluid,
J. Neurochem. 61 (1993) 1965-1968; DOI: 10.1111/j.1471-4159.1993.tb09841.x. - P. Seubert, C. Vigo-Pelfrey, F. Esch, M. Lee, H. Dovey, D. Davis, S. Sinha, M. Schiossmacher, J. Whaley, C. Swindlehurst, R. McCormack, R. Wolfert, D. Selkoe, I. Lieberburg and D. Schenk, Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids,
Nature 359 (1992) 325-327; DOI: 10.1038/359325a0. - J. T. Jarret, E. P. Berger and P. T. Lansbury, The C-terminus of the β protein is critical in amyloidogenesis,
Ann. NY Acad. Sci. USA 695 (1993) 144-148; DOI: 10.1111/j.1749-6632.1993.tb23043.x. - A. Lorenzo and B. A. Yankner, Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red,
Proc. Natl. Acad. Sci. USA 91 (1994) 12243-12247; DOI: 10.1073/pnas.91.25.12243. - J. Hardy and D. J. Selkoe, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics,
Science 297 (2002) 353-356; DOI: 10.1126/science.1072994. - H. Kozlowski, A. Janicka-Klos, J. Brasun, E. Gaggelli, D. Valensin and G. Valensin, Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation),
Coord. Chem. Rev. 253 (2009) 2665-2685; DOI: 10.1016/j.ccr.2009.05.011. - Y. Hung, A. Bush and R. Cherny, Copper in the brain and Alzheimer's disease,
J. Biol. Inorg. Chem. 15 (2010) 61-76; DOI: 10.1007/s00775-009-0600-y. - P. J. Crouch, K. J. Barnham, A. I. Bush and A. R. White, Therapeutic Treatments for Alzheimer's disease based on metal bioavailability,
Drug News Perspect. 19 (2006) 469-474; DOI: 10.1358/dnp.2006.19.8.1021492. - M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell and W. R. Markesbery, Copper, iron and zinc in Alzheimer's disease senile plaques,
J. Neurol. Sci. 158 (1998) 47-52; DOI: 10.1016/S0022-510X(98)00092-6. - C. S. Atwood, R. D. Moir, X. Huang, R. C. Scarpa, N. M. E. Bacarra, D. M. Romano, M. A. Hartshorn, R. E. Tanzi and A. I. Bush, Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis,
J. Biol. Chem. 273 (1998) 12817-12826; DOI: 10.1074/jbc.273.21.12817. - B. Raman, T. Ban, K.-I. Yamaguchi, M. Sakai, T. Kawai, H. Naiki and Y. Goto, Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid β peptide,
J. Biol. Chem. 280 (2005) 16157-16162; DOI: 10.1074/jbc.M500309200. - P. Faller, Copper and zinc binding to amyloid-β: Coordination, dynamics, aggregation, reactivity and metal-ion transfer,
ChemBioChem 10 (2009) 2837-2845; DOI: 10.1002/cbic.200900321. - C. Hureau and P. Faller, A[beta]-mediated ROS production by Cu ions: Structural insights, mechanisms and relevance to Alzheimer's disease,
Biochimie 91 (2009) 1212-1217; DOI: 10.1016/j.biochi.2009.03.013. - M. A. Deibel, W. D. Ehmann and W. R. Markesbery, Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress,
J. Neurol. Sci. 143 (1996) 137-142; DOI: 10.1016/S0022-510X(96)00203-1. - M. C. Boll, M. Alcaraz-Zubeldia, S. Montes and C. Rios, Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases,
Neurochem. Res. 33 (2008) 1717-1723; DOI: 10.1007/s11064-008-9610-3. - I. Maurer, S. Zierz and H. J. Moller, A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients,
Neurobiol. Aging 21 (2000) 455-462; DOI: 10.1016/S0197-4580(00) 00112-3. - Q. Ma, Y. Li, J. Du, H. Liu, K. Kanazawa, T. Nemoto, H. Nakanishi and Y. Zhao, Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS,
Peptides 27 (2006) 841-849; DOI: 10.1016/j.peptides.2005.09.002. - N. T. Watt, I. J. Whitehouse and N. M. Hooper, The role of zinc in Alzheimer's disease,
Int. J. Alzheimer's Dis. 2011 (2011) in press; DOI: 10.4061/2011/971021. - A. Bush, W. Pettingell, G. Multhaup, M. D. Paradis, J. Vonsattel, J. Gusella, K. Beyreuther, C. Masters and R. Tanzi, Rapid induction of Alzheimer A beta amyloid formation by zinc,
Science 265 (1994) 1464-1467; DOI: 10.1126/science.8073293. - K. H. Lim, Y. K. Kim and Y.-T. Chang, Investigations of the molecular mechanism of metal-induced Aβ (1-40) amyloidogenesis,
Biochemistry 46 (2007) 13523-13532; DOI: 10.1021/bi701112z. - C. Talmard, L. Guilloreau, Y. Coppel, H. Mazarguil, and P. Faller, Amyloid-beta peptide forms monomeric complexes with CuII and ZnII prior to aggregation,
ChemBioChem 8 (2007) 163-165; DOI: 10.1002/cbic.200600319. - M. P. Cuajungco and K. Y. Faget, Zinc takes the center stage: its paradoxical role in Alzheimer's disease,
Brain Res. Rev. 41 (2003) 44-56; DOI: 10.1016/S0165-0173(02)00219-9. - Z.-Y. Mo, Y.-Z. Zhu, H.-L. Zhu, J.-B. Fan, J. Chen and Y. Liang, Low micromolar zinc accelerates the fibrillization of human tau via bridging of Cys-291 and Cys-322,
J. Biolog. Chem. 284 (2009) 34648-34657; DOI: 10.1074/jbc.M109.058883. - P. W. Mantyh, J. R. Ghilardi, S. Rogers, E. DeMaster, C. J. Allen, E. R. Stimson and J. E. Maggio, Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide,
J. Neurochem. 61 (1993) 1171-1174; DOI: 10.1111/j.1471-4159.1993.tb03639.x. - C. Opazo, X. Huang, R. A. Cherny, R. D. Moir, A. E. Roher, A. R. White, R. Cappai, C. L. Masters, R. E. Tanzi, N. C. Inestrosa and A. I. Bush, Metalloenzyme-like activity of Alzheimer's disease β-amyloid,
J. Biol. Chem. 277 (2002) 40302-40308; DOI: 10.1074/jbc.M206428200. - D. G. Smith, R. Cappai and K. J. Barnham, The redox chemistry of the Alzheimer's disease amyloid beta peptide,
Biochim. Biophysi. Acta - Biomembranes 1768 (2007) 1976-1990; DOI: 10.2217/14796708.2.4.397. - P. F. Good, D. P. Perl, L. M. Bierer and J. Schmeidler, Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study,
Ann. Neurol. 31 (1992) 286-292; DOI: 10.1002/ana.410310310. - I. Klatzo, H. Wisniewski and E. Streicher, Experimental production of neurofibrillary degeneration: 1. Light microscopic observations,
J. Neuropathol. Exp. Neurol. 24 (1965) 187-199; DOI: 10.1097/00005072-196504000-00002. - R. D. Terry and C. Pena, Experimental production of neurofibrillary degeneration: 2. Electron microscopy, phosphatase histochemistry and electron prose analysis,
J. Neuropathol. Exp. Neurol. 24 (1965) 200-210; DOI: 10.1097/00005072-196504000-00003. - D. Drago, M. Bettella, S. Bolognin, L. Cendron, J. Scancar, R. Milacic, F. Ricchelli, A. Casini, L. Messori, G. Tognon and P. Zatta, Potential pathogenic role of β-amyloid1-42-aluminum complex in Alzheimer's disease,
Int. J. Biochem. Cell Biol. 40 (2008) 731-746; DOI: 10.1016/j.biocel.2007.10.014. - A. Rauk, The chemistry of Alzheimer's disease,
Chem. Soc. Rev. 38 (2009) 2698-2715; DOI: 10.1039/b807980n. - L. E. Scott and C. Orvig, Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease,
Chem. Rev. 109 (2009) 4885-4910; DOI: 10.1021/cr9000176. - J. A. Duce and A. I. Bush, Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics,
Prog. Neurobiol. 92 (2010) 1-18; DOI: 10.1016/j.pneurobio.2010.04.003. - I. Bush and R. E. Tanzi, Therapeutics for Alzheimer's disease based on the metal hypothesis,
Neurotherapeutics 5 (2008) 421-432; DOI: 10.1016/j.nurt.2008.05.001. - A. Gaeta and R. C. Hider, The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy,
Br. J. Pharmacol. 146 (2005) 1041-1059; DOI: 10.1038/sj.bjp.0706416. - P. Zatta, D. Drago, S. Bolognin and S. L. Sensi, Alzheimer's disease, metal ions and metal homeostatic therapy,
Trends Pharmacol. Sci. 30 (2009) 346-355; DOI: 10.1016/j.tips.2009.05.002. - L. R. Perez and K. J. Franz, Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease,
Dalton Trans. 39 (2010) 2177-2187; DOI: 10.1039/b919237a. - D. R. C. McLachlan, T. P. A. Kruck, W. Kalow, D. F. Andrews, A. J. Dalton, M. Y. Bell and W. L. Smith, Intramuscular desferrioxamine in patients with Alzheimer's disease,
Lancet 337 (1991) 1304-1308; DOI: 10.1016/0140-6736(91)92978-B. - R. A. Cherny, J. T. Legg, C. A. McLean, D. P. Fairlie, X. Huang, C. S. Atwood, K. Beyreuther, R. E. Tanzi, C. L. Masters and A. I. Bush, Aqueous dissolution of Alzheimer's disease abeta amyloid deposits by biometal depletion,
J. Biol. Chem. 274 (1999) 23223-23228; DOI: 10.1074/jbc.274.33.23223. - R. A. Cherny, K. J. Barnham, T. Lynch, I. Volitakis, Q.-X. Li, C. A. McLean, G. Multhaup, K. Beyreuther, R. E. Tanzi, C. L. Masters and A. I. Bush, Chelation and intercalation: Complementary properties in a compound for the treatment of Alzheimer's disease,
J. Struct. Biol. 130 (2000) 209-216; DOI: 10.1006/jsbi.2000.4285. - C. Boldron, I. Van der Auwera, C. Deraeve, H. Gornitzka, S. Wera, M. Pitié, F. Van Leuven and B. Meunier, Preparation of cyclo-phen-type ligands: Chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases,
ChemBioChem 6 (2005) 1976-1980; DOI: 10.1002/cbic.200500220. - A. Dedeoglu, K. Cormier, S. Payton, K. A. Tseitlin, J. N. Kremsky, L. Lai, X. Li, R. D. Moir, R. E. Tanzi, A. I. Bush, N. W. Kowall, J. T. Rogers and X. Huang, Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis,
Exp. Gerontol. 39 (2004) 1641-1649; DOI: 10.1016/j.exger.2004.08.016. - Z. Cui, P. R. Lockman, C. S. Atwood, C.-H. Hsu, A. Gupte, D. D. Allen and R. J. Mumper, Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases,
Eur. J. Pharm. Biopharm. 59 (2005) 263-272; DOI: 10.1016/j.ejpb.2004.07.009. - J.-Y. Lee, J. E. Friedman, I. Angel, A. Kozak and J.-Y. Koh, The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human [beta]-amyloid precursor protein transgenic mice,
Neurobiol. Aging 25 (2004) 1315-1321; DOI: 10.1016/j.neurobiolaging.2004.01.005. - V. Moret, Y. Laras, N. Pietrancosta, C. Garino, G. Quelever, A. Rolland, B. Mallet, J. C. Norreel and J. L. Kraus, 1,1 '-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: A new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution,
Bioorg. Med. Chem. Lett. 16 (2006) 3298-3301; DOI: 10.1016/j.bmcl.2006.03.026. - H. Zheng, S. Gal, L. M. Weiner, O. Bar-Am, A. Warshawsky, M. Fridkin and M. B. H. Youdim, Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases:
in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition,J. Neurochem. 95 (2005) 68-78; DOI: 10.1111/j.1471-4159.2005.03340.x. - D. Kaur, F. Yantiri, S. Rajagopalan, J. Kumar, J. Q. Mo, R. Boonplueang, V. Viswanath, R. Jacobs, L. Yang, M. F. Beal, D. DiMonte, I. Volitaskis, L. Ellerby, R. A. Cherny, A. I. Bush and J. K. Andersen, Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease,
Neuron 37 (2003) 899-909; DOI: 10.1016/S0896-6273 (03)00126-0. - R. A. Cherny, C. S. Atwood, M. E. Xilinas, D. N. Gray, W. D. Jones, C. A. McLean, K. J. Barnham, I. Volitakis, F. W. Fraser, Y.-S. Kim, X. Huang, L. E. Goldstein, R. D. Moir, J. T. Lim, K. Beyreuther, H. Zheng, R. E. Tanzi, C. L. Masters and A. I. Bush, Treatment with a copper-zinc chelator markedly and rapidly inhibits [beta]-amyloid accumulation in Alzheimer's disease transgenic mice,
Neuron 30 (2001) 665-676; DOI: 10.1016/S0896-6273(01)00317-8. - H. Zheng, M. B. H. Youdim, L. M. Weiner and M. Fridkin, Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases,
J. Pept. Res. 66 (2005) 190-203; DOI: 10.1111/j.1399-3011.2005.00289.x. - C. Deraeve, M. Pitie, H. Mazarguil and B. Meunier, Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents,
New J. Chem. 31 (2007) 193-195; DOI: 10.1039/b616085a. - C. W. Ritchie, A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q.-X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R. E. Tanzi and C. L. Masters, Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial,
Arch. Neurol. 60 (2003) 1685-1691; DOI: 10.1001/archneur.60.12.1685. - A. I. Bush, Metal complexing agents as therapies for Alzheimer's disease,
Neurobiol. Aging 23 (2002) 1031-1038. DOI: 10.1016/S0197-4580(02)00120-3. - J. Tateishi, Subacute myelo-optico-neuropathy: Clioquinol intoxication in humans and animals,
Neuropathology 20 (Suppl.) S20-S24; DOI: 10.1046/j.1440-1789.2000.00296.x. - M. S. Yassin, J. Ekblom, M. Xilinas, C. G. Gottfries and L. Oreland, Changes in uptake of vitamin B-12 and trace metals in brains of mice treated with clioquinol,
J. Neurol. Sci 173 (2000) 40-44; DOI: 10.1016/S0022-510X(99)00297-X. - M. Di Vaira, C. Bazzicalupi, P. Orioli, L. Messori, B. Bruni and P. Zatta, Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: Structural characterization of its zinc(II) and copper(II) complexes,
Inorg. Chem. 43 (2004) 3795-3797; DOI: 10.1021/ic0494051. - C. C. Wagner, S. Calvo, M. H. Torre and E. J. Baran, Vibrational spectra of clioquinol and its Cu(II) complex,
J. Raman Spectrosc. 38 (2007) 373-376; DOI: 10.1002/jrs.1654. - A. Budimir, N. Humbert, M. Elhabiri, I. Osinska, M. Birus and A.-M. Albrecht-Gary, Hydroxyquinoline based binders: Promising ligands for chelatotherapy?,
J. Inorg. Biochem , in press; DOI: 10.1016/j.jinorgbio.2010.08.014. - R. A. Cherny, J. T. Legg, C. A. McLean, D. P. Fairlie, X. Huang, C. S. Atwood, K. Beyreuther, R. E. Tanzi, C. L. Masters and A. I. Bush, Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion,
J. Biol. Chem. 274 (1999) 23223-23228; DOI: 10.1074/jbc.274.33.23223. - C. Grossi, S. Francese, A. Casini, M. C. Rosi, I. Luccarini, A. Fiorentini, C. Gabbiani, L. Messori, G. Moneti and F. Casamenti, Clioquinol decreases amyloid-β burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease,
J. Alzheimer's Dis. 17 (2009) 423-440. - L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, J. Harrison, C. L. Masters, S. Targum, A. I. Bush, R. Murdoch, J. Wilson and C. W. Ritchie, Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial,
Lancet Neurol. 7 (2008) 779-786; DOI: 10.1016/S1474-4422(08)70167-4. - P. A. Adlard, R. A. Cherny, D. I. Finkelstein, E. Gautier, E. Robb, M. Cortes, I. Volitakis, X. Liu, J. P. Smith, K. Perez, K. Laughton, Q.-X. Li, S. A. Charman, J. A. Nicolazzo, S. Wilkins, K. Deleva, T. Lynch, G. Kok, C. W. Ritchie, R. E. Tanzi, R. Cappai, C. L. Masters, K. J. Barnham and A. I. Bush, Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ,
Neuron 59 (2008) 43-55; DOI: 10.1016/j.neuron.2008.06.018.
Language: English
Page range: 1 - 14
Published on: Mar 15, 2011
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2011 Ana Budimir, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.